As of 2026-10-11, the Relative Valuation of Lineage Cell Therapeutics Inc (LCTX) is (0.10) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.99 USD, the upside of Lineage Cell Therapeutics Inc based on Relative Valuation is -110.1%.
The range of the Relative Valuation is (0.28) - (0.02) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 2.2x - 3.2x | 2.7x |
| Forward P/E multiples | -2.5x - 0.2x | -1.2x |
| Fair Price | (0.28) - (0.02) | (0.10) |
| Upside | -128.1% - -102.1% | -110.1% |
| Date | P/E |
| 2026-10-09 | -7.68 |
| 2026-10-08 | -7.96 |
| 2026-10-07 | -7.32 |
| 2026-10-06 | -7.25 |
| 2026-10-05 | -7.17 |
| 2026-10-02 | -7.19 |
| 2026-10-01 | -6.99 |
| 2026-09-30 | -7.39 |
| 2026-09-29 | -7.32 |
| 2026-09-28 | -7.50 |
| 2026-09-25 | -7.96 |
| 2026-09-24 | -7.32 |
| 2026-09-23 | -7.39 |
| 2026-09-22 | -8.04 |
| 2026-09-21 | -7.81 |
| 2026-09-18 | -7.96 |
| 2026-09-17 | -7.96 |
| 2026-09-16 | -8.27 |
| 2026-09-15 | -8.19 |
| 2026-09-14 | -8.27 |
| 2026-09-11 | -7.81 |
| 2026-09-10 | -7.88 |
| 2026-09-09 | -7.96 |
| 2026-09-08 | -8.42 |
| 2026-09-04 | -8.35 |
| 2026-09-03 | -8.50 |
| 2026-09-02 | -8.58 |
| 2026-09-01 | -8.35 |
| 2026-08-31 | -8.50 |
| 2026-08-28 | -8.58 |
| 2026-08-27 | -8.96 |
| 2026-08-26 | -8.66 |
| 2026-08-25 | -8.73 |
| 2026-08-24 | -8.42 |
| 2026-08-21 | -8.35 |
| 2026-08-20 | -8.35 |
| 2026-08-19 | -8.50 |
| 2026-08-18 | -8.19 |
| 2026-08-17 | -8.19 |
| 2026-08-14 | -8.27 |
| 2026-08-13 | -8.19 |
| 2026-08-12 | -8.50 |
| 2026-08-11 | -8.66 |
| 2026-08-10 | -8.73 |
| 2026-08-07 | -8.50 |
| 2026-08-06 | -8.73 |
| 2026-08-05 | -8.81 |
| 2026-08-04 | -8.66 |
| 2026-08-03 | -8.58 |
| 2026-07-31 | -8.35 |